查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1856133

全球胜肽合成市场－市场份额和排名、总收入和需求预测（2025-2031 年）

Peptide Synthesis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 132 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球胜肽合成市场规模估计为 6.99 亿美元，预计到 2031 年将达到 10.94 亿美元，在 2025-2031 年预测期内复合年增长率为 6.7%。

胜肽合成是指利用化学或生物化学方法将特定序列的多个胺基酸连接成胜肽链的过程。这些胜肽可用作治疗药物、诊断剂、生物标记和研究工具。胜肽通常比蛋白质短，通常由不超过40-60个胺基酸残基组成，但其结构可能很复杂，可能包含非天然或修饰的胺基酸、环化、与化学基团偶联以及标记。主要的胜肽合成技术包括固相胜肽合成（SPPS）、液相胜肽合成（LPPS）、混合/汇聚合成法、酵素法和重组表现。合成流程通常包括胺基酸的保护和去保护、胜肽键形成（偶联）、载体/树脂锚定、纯化（层析法步骤、沉淀等）以及严格的品管（结构确认、立体化学纯度、杂质/残留溶剂分析）。肽类药物、诊断和化妆品应用的快速发展，以及对高特异性、低毒性和强生物相容性的需求不断增长，使得肽合成成为生物製药和生命科学研究与开发的关键组成部分。

目前，肽合成市场正处于曲折点。一方面，基于胜肽的疗法在慢性病、代谢性疾病、肿瘤和神经退化等领域日益普及。其高特异性、低全身毒性和新型标靶机制使其在传统小分子和大蛋白药物难以发挥作用的领域展现出巨大潜力。另一方面，许多国家（例如美国、欧盟、日本和中国）的政府和监管机构已推出政策，支持创新，简化新型胜肽和胜肽-寡核苷酸（TIDES）药物的核准途径，并缩短临床试验和监管审查时间，从而扩大了胜肽合成供应商的市场机会。在技​​术方面，固相合成（SPPS）、液相合成（LPPS）、混合/汇聚合成方法的不断进步，以及复杂结构（包括非天然氨基酸、环化和胜肽-药物偶联物）合成能力的提升，正推动市场朝着更大规模、更高品质和更多样化的结构发展。此外，下游CDMO/CRO外包需求正在迅速成长。药物研发企业越来越倾向于将製程开发、规模化生产以及临床/註册生产外包给专业的合成/生产营业单位，以降低资本负担和风险。新兴经济体（例如中国、印度和韩国）也是这一趋势的强劲驱动力，这得益于不断增长的医疗需求、对生物技术的投资、不断下降的生产成本以及有利的政策激励措施。

然而，肽合成市场并非没有重大挑战和风险。首先，合成长肽或复杂胜肽（例如，带有修饰、非天然残基、环化或疏水序列的胜肽）时，偶联效率低、反应不完全、外消旋化和副产物生成等问题会被放大，导致产率降低，纯化成本高且难度高。其次，上游原料（高纯度保护胺基酸、专用耦合试剂、保护基以及稀有或合成修饰胺基酸）的供应链稳定性和成本差异很大。第三，下游纯化和品管步骤（层析法、去除残留试剂、保护基和溶剂、结构确认和立体化学纯度测定）需要大量的资本投入、较长的週期和较高的营运成本，尤其是在临床和商业规模上。各国对胜肽和生技药品（或其他类别）的定义、监管标准以及环境和化学安全政策的差异，会增加合规成本并导致延误。最后，竞争压力和价格战正在加剧，尤其是在 CDMO/合成服务供应商和以成本为导向的新兴市场。

下游需求正朝着多个方向同步发展。治疗性胜肽仍然是最大的驱动力。越来越多的胜肽类药物获得监管部门核准，研发开发平臺也不断扩展，尤其是在代谢性疾病（如肥胖症、糖尿病）、肿瘤、内分泌调节和感染疾病等领域。肽-药物偶联物和胜肽疫苗已成为多个疾病领域的关键研究方向。除了治疗性应用外，诊断和成像标记肽，例如生物标记、体外诊断试剂（IVD）以及放射性标记或萤光标记的小肽，需求也在不断增长，尤其是在精准医疗领域。在化妆品/美容行业，具有抗衰老、修復、促进胶原蛋白生成和抗氧化等功能的胜肽正被积极引入市场，从而推动了消费者和品牌对天然、生物活性和安全成分的更高期望。在自动化和高通量合成工具的推动下，研究和基础科学需求保持稳定，这促使学术机构和生物技术新兴企业寻求更灵活、更快速的客製化胜肽合成服务。总体而言，下游需求正朝着更复杂的结构、更先进的改进、更高的纯度和更客製化的应用方向发展，这要求更快的周转时间和更高的服务品质。

本报告旨在全面概述全球胜肽合成市场，重点关注总销售收入、市场份额和主要企业的排名，并按地区/国家、类型和应用进行分析。

胜肽合成市场规模、估算和预测报告提供了2020年至2031年期间的历史数据和预测数据，以销售收入（百万美元）为单位，2024年为基准年。定量和定性分析有助于读者制定业务/成长策略、评估市场竞争格局、分析公司在当前市场中的地位，并在胜肽合成领域做出明智的商业决策。

目录

第一章 市场概览

  • 胜肽合成产品介绍
  • 全球胜肽合成市场规模预测（2020-2031年）
  • 肽合成市场趋势及驱动因素
  • 先决条件和限制
  • 调查目的
  • 考虑的年数

第二章 竞争分析：依公司划分

  • 全球肽合成公​​司收入排名（2024）
  • 全球肽合成公​​司收入（按公司划分）（2020-2025 年）
  • 主要企业製造地和总部分布情况
  • 主要企业提供的胜肽合成产品
  • 主要企业何时才能开始大规模生产胜肽合成产品？
  • 胜肽合成市场竞争分析
  • 併购、业务扩张

第三章 按类型分類的章节

  • 简介：按类型
    • 原料药和中介软体
    • 胜肽製剂
  • 全球胜肽合成销售金额（按类型划分）

第四章 章节：按应用

  • 引言：透过申请
    • 商业的
    • 学术研究
  • 全球胜肽合成产品销售金额（按应用领域划分）

第五章 章节划分：依地区

  • 全球胜肽合成产品销售金额（按地区划分）
  • 北美洲
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东和非洲

第六章 章节：依主要国家划分

  • 主要国家/地区胜肽合成销售金额成长趋势（2020年、2024年、2031年）
  • 2020-2031年主要国家/地区胜肽合成销售金额
  • 美国
  • 欧洲
  • 中国
  • 日本
  • 韩国
  • 东南亚
  • 印度

第七章 公司简介

  • Bachem
  • PolyPeptide
  • CordenPharma
  • AmbioPharm
  • USV Peptides
  • Thermofischer
  • Bio Basic
  • JPT
  • Genscript
  • Xinbang Pharma
  • ScinoPharm
  • SN Biopharm
  • CBL
  • Piramal Pharma
  • CPC Scientific
  • Shenzhen Hanyu

第八章：产业链分析

第九章 研究结果与结论

第十章附录

The global market for Peptide Synthesis was estimated to be worth US$ 699 million in 2024 and is forecast to a readjusted size of US$ 1094 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.

Peptide synthesis refers to the process of linking multiple amino acids into a peptide chain in a specified sequence by chemical or biochemical methods. These peptides may serve as therapeutics, diagnostic reagents, biomarkers, or research tools. Peptides are generally shorter than proteins - most often composed of no more than 40-60 amino acid residues - though their structures can be complex, including non-natural or modified amino acids, cyclizations, conjugations with chemical moieties or labels. The main techniques for peptide synthesis include solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), hybrid/convergent methods, enzymatic or recombinant expression methods. The synthetic workflow typically involves protecting and deprotecting amino acids, peptide bond formation (coupling), support/resin anchoring or carrier systems, purification (such as chromatographic steps, precipitations, etc.), and rigorous quality control (structure confirmation, stereochemical purity, impurity/residual solvent analysis). With the rapid expansion of peptide-based drugs, diagnostics, and cosmetic applications, combined with growing demand for high specificity, low toxicity, and strong biocompatibility, peptide synthesis has become a cornerstone in biopharma and life science R&D.

The peptide synthesis market currently stands at a multi-accelerated inflection point. On one side, peptide-based therapeutics are being increasingly recognized in fields such as chronic diseases, metabolic disorders, oncology, and neurodegeneration: their high specificity, low systemic toxicity, and novel targeting mechanisms make them promising where traditional small molecules or large proteins struggle. On another side, governments and regulatory agencies in many countries (including the U.S., EU, Japan, China, etc.) are introducing policies that support innovation, streamline approval pathways for novel peptides or peptide/oligonucleotide (TIDES) drugs, and shorten clinical trial and regulatory review timelines, thereby enlarging market opportunity for peptide synthesis providers. On the technical front, continued progress in solid-phase synthesis (SPPS), liquid-phase methods (LPPS), hybrid / convergent synthesis, and enhanced capabilities for complex structures (including non-natural amino acids, cyclization, peptide-drug conjugates) are pushing the market toward larger scale, higher quality, and greater structural diversity. In addition, downstream CDMO/CRO outsourcing demand is rising sharply: drug developers are increasingly preferring to externalize process development, scale-up, and clinical/registration production to specialized synthesis/manufacturing entities to reduce capital burden and risk. Emerging economies (e.g. China, India, South Korea) are also providing strong growth drivers due to their rising healthcare needs, biotech investment, lower manufacturing cost bases, and favorable policy incentives.

However, the peptide synthesis market is not without substantial challenges and risks. First, synthesizing long or complex peptides (with modifications, non-natural residues, cyclization, hydrophobic sequences etc.) amplifies problems of low coupling efficiency, incomplete reactions, racemization, side-product formation - these reduce yield and make purification expensive and difficult. Second, the supply chain stability and cost volatility for upstream raw materials (high-purity protected amino acids, specialized coupling reagents, protective groups, rare or synthetic modified amino acids) is high; environmental / safety laws regulating chemical reagents and solvents impose increasing constraints. Third, downstream purification and quality control steps (chromatography, removal of residual reagents/protection groups/solvents, structure confirmation, stereochemical purity) require heavy equipment investment, long cycles, and high operating costs, particularly at clinical/commercial scale. Regulatory risk is also real: differing national definitions of peptides vs biologics (or other categories), regulatory standards, and environmental / chemical safety policies may shift, increasing compliance cost or causing delays. Finally, competitive pressures and pricing squeeze are intensifying, especially among CDMOs / synthesis service providers, and in emerging markets focusing on low cost; maintaining high quality, speed, and regulatory compliance becomes a differentiator but also a cost center.

Downstream demand is evolving in several concurrent directions. Therapeutic peptides continue to be the largest pull: more peptide drugs are gaining regulatory approval, and the R&D pipeline is expanding, especially in metabolic disease (e.g. obesity, diabetes), oncology, endocrine regulation, and infectious diseases. In several disease areas, peptide-drug conjugates and peptide vaccines are emerging as key focus areas. Beyond therapeutics, diagnostic and imaging labelled peptides are growing demand, e.g. biomarkers, in vitro diagnostics (IVD) and radiolabelled or fluorescent labelled small peptides, especially in precision medicine. The cosmetics / beauty sector is also actively introducing peptides with anti-aging, repair, collagen-boosting, antioxidative functionalities, with rising consumer and brand expectations for natural or bio-active, safety validated ingredients. Research and basic science needs remain stable, being driven by automation and high-throughput synthesis tools, giving academic institutions and biotech startups need for more flexible, fast, custom peptide synthesis services. Overall, downstream demand is trending toward more complex structures / high modifications / higher purity / more individualized use, and demands for faster turnaround and higher service quality.

This report aims to provide a comprehensive presentation of the global market for Peptide Synthesis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Peptide Synthesis by region & country, by Type, and by Application.

The Peptide Synthesis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Synthesis.

Market Segmentation

By Company

  • Bachem
  • PolyPeptide
  • CordenPharma
  • AmbioPharm
  • USV Peptides
  • Thermofischer
  • Bio Basic
  • JPT
  • Genscript
  • Xinbang Pharma
  • ScinoPharm
  • SN Biopharm
  • CBL
  • Piramal Pharma
  • CPC Scientific
  • Shenzhen Hanyu

Segment by Type

  • APIs and Intermediates
  • Peptide preparations

Segment by Application

  • Commercial
  • Academic Research

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Peptide Synthesis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Peptide Synthesis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Peptide Synthesis in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Peptide Synthesis Product Introduction
  • 1.2 Global Peptide Synthesis Market Size Forecast (2020-2031)
  • 1.3 Peptide Synthesis Market Trends & Drivers
    • 1.3.1 Peptide Synthesis Industry Trends
    • 1.3.2 Peptide Synthesis Market Drivers & Opportunity
    • 1.3.3 Peptide Synthesis Market Challenges
    • 1.3.4 Peptide Synthesis Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Peptide Synthesis Players Revenue Ranking (2024)
  • 2.2 Global Peptide Synthesis Revenue by Company (2020-2025)
  • 2.3 Key Companies Peptide Synthesis Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Peptide Synthesis Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Peptide Synthesis
  • 2.6 Peptide Synthesis Market Competitive Analysis
    • 2.6.1 Peptide Synthesis Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Peptide Synthesis Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Synthesis as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 APIs and Intermediates
    • 3.1.2 Peptide preparations
  • 3.2 Global Peptide Synthesis Sales Value by Type
    • 3.2.1 Global Peptide Synthesis Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Peptide Synthesis Sales Value, by Type (2020-2031)
    • 3.2.3 Global Peptide Synthesis Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Commercial
    • 4.1.2 Academic Research
  • 4.2 Global Peptide Synthesis Sales Value by Application
    • 4.2.1 Global Peptide Synthesis Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Peptide Synthesis Sales Value, by Application (2020-2031)
    • 4.2.3 Global Peptide Synthesis Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Peptide Synthesis Sales Value by Region
    • 5.1.1 Global Peptide Synthesis Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Peptide Synthesis Sales Value by Region (2020-2025)
    • 5.1.3 Global Peptide Synthesis Sales Value by Region (2026-2031)
    • 5.1.4 Global Peptide Synthesis Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Peptide Synthesis Sales Value, 2020-2031
    • 5.2.2 North America Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Peptide Synthesis Sales Value, 2020-2031
    • 5.3.2 Europe Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Peptide Synthesis Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Peptide Synthesis Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Peptide Synthesis Sales Value, 2020-2031
    • 5.5.2 South America Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Peptide Synthesis Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Peptide Synthesis Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Peptide Synthesis Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Peptide Synthesis Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Peptide Synthesis Sales Value, 2020-2031
    • 6.3.2 United States Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Peptide Synthesis Sales Value, 2020-2031
    • 6.4.2 Europe Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Peptide Synthesis Sales Value, 2020-2031
    • 6.5.2 China Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Peptide Synthesis Sales Value, 2020-2031
    • 6.6.2 Japan Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Peptide Synthesis Sales Value, 2020-2031
    • 6.7.2 South Korea Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Peptide Synthesis Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Peptide Synthesis Sales Value, 2020-2031
    • 6.9.2 India Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Peptide Synthesis Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Bachem
    • 7.1.1 Bachem Profile
    • 7.1.2 Bachem Main Business
    • 7.1.3 Bachem Peptide Synthesis Products, Services and Solutions
    • 7.1.4 Bachem Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Bachem Recent Developments
  • 7.2 PolyPeptide
    • 7.2.1 PolyPeptide Profile
    • 7.2.2 PolyPeptide Main Business
    • 7.2.3 PolyPeptide Peptide Synthesis Products, Services and Solutions
    • 7.2.4 PolyPeptide Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.2.5 PolyPeptide Recent Developments
  • 7.3 CordenPharma
    • 7.3.1 CordenPharma Profile
    • 7.3.2 CordenPharma Main Business
    • 7.3.3 CordenPharma Peptide Synthesis Products, Services and Solutions
    • 7.3.4 CordenPharma Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.3.5 CordenPharma Recent Developments
  • 7.4 AmbioPharm
    • 7.4.1 AmbioPharm Profile
    • 7.4.2 AmbioPharm Main Business
    • 7.4.3 AmbioPharm Peptide Synthesis Products, Services and Solutions
    • 7.4.4 AmbioPharm Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.4.5 AmbioPharm Recent Developments
  • 7.5 USV Peptides
    • 7.5.1 USV Peptides Profile
    • 7.5.2 USV Peptides Main Business
    • 7.5.3 USV Peptides Peptide Synthesis Products, Services and Solutions
    • 7.5.4 USV Peptides Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.5.5 USV Peptides Recent Developments
  • 7.6 Thermofischer
    • 7.6.1 Thermofischer Profile
    • 7.6.2 Thermofischer Main Business
    • 7.6.3 Thermofischer Peptide Synthesis Products, Services and Solutions
    • 7.6.4 Thermofischer Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Thermofischer Recent Developments
  • 7.7 Bio Basic
    • 7.7.1 Bio Basic Profile
    • 7.7.2 Bio Basic Main Business
    • 7.7.3 Bio Basic Peptide Synthesis Products, Services and Solutions
    • 7.7.4 Bio Basic Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Bio Basic Recent Developments
  • 7.8 JPT
    • 7.8.1 JPT Profile
    • 7.8.2 JPT Main Business
    • 7.8.3 JPT Peptide Synthesis Products, Services and Solutions
    • 7.8.4 JPT Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.8.5 JPT Recent Developments
  • 7.9 Genscript
    • 7.9.1 Genscript Profile
    • 7.9.2 Genscript Main Business
    • 7.9.3 Genscript Peptide Synthesis Products, Services and Solutions
    • 7.9.4 Genscript Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Genscript Recent Developments
  • 7.10 Xinbang Pharma
    • 7.10.1 Xinbang Pharma Profile
    • 7.10.2 Xinbang Pharma Main Business
    • 7.10.3 Xinbang Pharma Peptide Synthesis Products, Services and Solutions
    • 7.10.4 Xinbang Pharma Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Xinbang Pharma Recent Developments
  • 7.11 ScinoPharm
    • 7.11.1 ScinoPharm Profile
    • 7.11.2 ScinoPharm Main Business
    • 7.11.3 ScinoPharm Peptide Synthesis Products, Services and Solutions
    • 7.11.4 ScinoPharm Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.11.5 ScinoPharm Recent Developments
  • 7.12 SN Biopharm
    • 7.12.1 SN Biopharm Profile
    • 7.12.2 SN Biopharm Main Business
    • 7.12.3 SN Biopharm Peptide Synthesis Products, Services and Solutions
    • 7.12.4 SN Biopharm Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.12.5 SN Biopharm Recent Developments
  • 7.13 CBL
    • 7.13.1 CBL Profile
    • 7.13.2 CBL Main Business
    • 7.13.3 CBL Peptide Synthesis Products, Services and Solutions
    • 7.13.4 CBL Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.13.5 CBL Recent Developments
  • 7.14 Piramal Pharma
    • 7.14.1 Piramal Pharma Profile
    • 7.14.2 Piramal Pharma Main Business
    • 7.14.3 Piramal Pharma Peptide Synthesis Products, Services and Solutions
    • 7.14.4 Piramal Pharma Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Piramal Pharma Recent Developments
  • 7.15 CPC Scientific
    • 7.15.1 CPC Scientific Profile
    • 7.15.2 CPC Scientific Main Business
    • 7.15.3 CPC Scientific Peptide Synthesis Products, Services and Solutions
    • 7.15.4 CPC Scientific Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.15.5 CPC Scientific Recent Developments
  • 7.16 Shenzhen Hanyu
    • 7.16.1 Shenzhen Hanyu Profile
    • 7.16.2 Shenzhen Hanyu Main Business
    • 7.16.3 Shenzhen Hanyu Peptide Synthesis Products, Services and Solutions
    • 7.16.4 Shenzhen Hanyu Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.16.5 Shenzhen Hanyu Recent Developments

8 Industry Chain Analysis

  • 8.1 Peptide Synthesis Industrial Chain
  • 8.2 Peptide Synthesis Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Peptide Synthesis Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Peptide Synthesis Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Peptide Synthesis Market Trends
  • Table 2. Peptide Synthesis Market Drivers & Opportunity
  • Table 3. Peptide Synthesis Market Challenges
  • Table 4. Peptide Synthesis Market Restraints
  • Table 5. Global Peptide Synthesis Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Peptide Synthesis Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Peptide Synthesis Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Peptide Synthesis Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Peptide Synthesis
  • Table 10. Global Peptide Synthesis Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Synthesis as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Peptide Synthesis Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Peptide Synthesis Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Peptide Synthesis Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Peptide Synthesis Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Peptide Synthesis Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Peptide Synthesis Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Peptide Synthesis Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Peptide Synthesis Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Peptide Synthesis Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Peptide Synthesis Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Peptide Synthesis Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Peptide Synthesis Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Peptide Synthesis Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Peptide Synthesis Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Peptide Synthesis Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Peptide Synthesis Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Peptide Synthesis Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Peptide Synthesis Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Bachem Basic Information List
  • Table 32. Bachem Description and Business Overview
  • Table 33. Bachem Peptide Synthesis Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Peptide Synthesis Business of Bachem (2020-2025)
  • Table 35. Bachem Recent Developments
  • Table 36. PolyPeptide Basic Information List
  • Table 37. PolyPeptide Description and Business Overview
  • Table 38. PolyPeptide Peptide Synthesis Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Peptide Synthesis Business of PolyPeptide (2020-2025)
  • Table 40. PolyPeptide Recent Developments
  • Table 41. CordenPharma Basic Information List
  • Table 42. CordenPharma Description and Business Overview
  • Table 43. CordenPharma Peptide Synthesis Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Peptide Synthesis Business of CordenPharma (2020-2025)
  • Table 45. CordenPharma Recent Developments
  • Table 46. AmbioPharm Basic Information List
  • Table 47. AmbioPharm Description and Business Overview
  • Table 48. AmbioPharm Peptide Synthesis Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Peptide Synthesis Business of AmbioPharm (2020-2025)
  • Table 50. AmbioPharm Recent Developments
  • Table 51. USV Peptides Basic Information List
  • Table 52. USV Peptides Description and Business Overview
  • Table 53. USV Peptides Peptide Synthesis Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Peptide Synthesis Business of USV Peptides (2020-2025)
  • Table 55. USV Peptides Recent Developments
  • Table 56. Thermofischer Basic Information List
  • Table 57. Thermofischer Description and Business Overview
  • Table 58. Thermofischer Peptide Synthesis Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Peptide Synthesis Business of Thermofischer (2020-2025)
  • Table 60. Thermofischer Recent Developments
  • Table 61. Bio Basic Basic Information List
  • Table 62. Bio Basic Description and Business Overview
  • Table 63. Bio Basic Peptide Synthesis Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Peptide Synthesis Business of Bio Basic (2020-2025)
  • Table 65. Bio Basic Recent Developments
  • Table 66. JPT Basic Information List
  • Table 67. JPT Description and Business Overview
  • Table 68. JPT Peptide Synthesis Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Peptide Synthesis Business of JPT (2020-2025)
  • Table 70. JPT Recent Developments
  • Table 71. Genscript Basic Information List
  • Table 72. Genscript Description and Business Overview
  • Table 73. Genscript Peptide Synthesis Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Peptide Synthesis Business of Genscript (2020-2025)
  • Table 75. Genscript Recent Developments
  • Table 76. Xinbang Pharma Basic Information List
  • Table 77. Xinbang Pharma Description and Business Overview
  • Table 78. Xinbang Pharma Peptide Synthesis Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Peptide Synthesis Business of Xinbang Pharma (2020-2025)
  • Table 80. Xinbang Pharma Recent Developments
  • Table 81. ScinoPharm Basic Information List
  • Table 82. ScinoPharm Description and Business Overview
  • Table 83. ScinoPharm Peptide Synthesis Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Peptide Synthesis Business of ScinoPharm (2020-2025)
  • Table 85. ScinoPharm Recent Developments
  • Table 86. SN Biopharm Basic Information List
  • Table 87. SN Biopharm Description and Business Overview
  • Table 88. SN Biopharm Peptide Synthesis Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Peptide Synthesis Business of SN Biopharm (2020-2025)
  • Table 90. SN Biopharm Recent Developments
  • Table 91. CBL Basic Information List
  • Table 92. CBL Description and Business Overview
  • Table 93. CBL Peptide Synthesis Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Peptide Synthesis Business of CBL (2020-2025)
  • Table 95. CBL Recent Developments
  • Table 96. Piramal Pharma Basic Information List
  • Table 97. Piramal Pharma Description and Business Overview
  • Table 98. Piramal Pharma Peptide Synthesis Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Peptide Synthesis Business of Piramal Pharma (2020-2025)
  • Table 100. Piramal Pharma Recent Developments
  • Table 101. CPC Scientific Basic Information List
  • Table 102. CPC Scientific Description and Business Overview
  • Table 103. CPC Scientific Peptide Synthesis Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Peptide Synthesis Business of CPC Scientific (2020-2025)
  • Table 105. CPC Scientific Recent Developments
  • Table 106. Shenzhen Hanyu Basic Information List
  • Table 107. Shenzhen Hanyu Description and Business Overview
  • Table 108. Shenzhen Hanyu Peptide Synthesis Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Peptide Synthesis Business of Shenzhen Hanyu (2020-2025)
  • Table 110. Shenzhen Hanyu Recent Developments
  • Table 111. Key Raw Materials Lists
  • Table 112. Raw Materials Key Suppliers Lists
  • Table 113. Peptide Synthesis Downstream Customers
  • Table 114. Peptide Synthesis Distributors List
  • Table 115. Research Programs/Design for This Report
  • Table 116. Key Data Information from Secondary Sources
  • Table 117. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Peptide Synthesis Product Picture
  • Figure 2. Global Peptide Synthesis Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Peptide Synthesis Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Peptide Synthesis Report Years Considered
  • Figure 5. Global Peptide Synthesis Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Peptide Synthesis Revenue in 2024
  • Figure 7. Peptide Synthesis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. APIs and Intermediates Picture
  • Figure 9. Peptide preparations Picture
  • Figure 10. Global Peptide Synthesis Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Peptide Synthesis Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Commercial
  • Figure 13. Product Picture of Academic Research
  • Figure 14. Global Peptide Synthesis Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Peptide Synthesis Sales Value Market Share by Application, 2024 & 2031
  • Figure 16. North America Peptide Synthesis Sales Value (2020-2031) & (US$ Million)
  • Figure 17. North America Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • Figure 18. Europe Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 19. Europe Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Asia Pacific Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Asia Pacific Peptide Synthesis Sales Value by Region (%), 2024 VS 2031
  • Figure 22. South America Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. South America Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Middle East & Africa Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Middle East & Africa Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Key Countries/Regions Peptide Synthesis Sales Value (%), (2020-2031)
  • Figure 27. United States Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. United States Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 29. United States Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 30. Europe Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Europe Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 32. Europe Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 33. China Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. China Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 35. China Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 36. Japan Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Japan Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Japan Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 39. South Korea Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. South Korea Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 41. South Korea Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Southeast Asia Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Southeast Asia Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Southeast Asia Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 45. India Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. India Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 47. India Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Peptide Synthesis Industrial Chain
  • Figure 49. Peptide Synthesis Manufacturing Cost Structure
  • Figure 50. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 51. Bottom-up and Top-down Approaches for This Report
  • Figure 52. Data Triangulation
  • Figure 53. Key Executives Interviewed